Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Financial Strength

6/10

Name	Current	Vs Industry
Cash-To-Debt	0.25
Equity-to-Asset	0.39
Debt-to-Equity	0.85
Debt-to-EBITDA	2.83
Interest Coverage	7.61
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	4.03	Distress Grey Safe
Beneish M-Score	-2.99	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

8/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	15.4
	3-Year EBITDA Growth Rate	23.9
	3-Year EPS without NRI Growth Rate	26.1
	3-Year FCF Growth Rate	14
	3-Year Book Growth Rate	21.1
	Future 3-5Y EPS without NRI Growth Rate	14.6
	Future 3-5Y Total Revenue Growth Rate	4.27

Momentum Rank

4/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	32.46
	9-Day RSI	35.53
	14-Day RSI	37.85
	6-1 Month Momentum %	-6.7
	12-1 Month Momentum %	-5.62

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.38
	Quick Ratio	1.12
	Cash Ratio	0.38
	Days Inventory	133.57
	Days Sales Outstanding	62.49
	Days Payable	82.85

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	2.93
	Dividend Payout Ratio	1.62
	3-Year Dividend Growth Rate	7.4
	Forward Dividend Yield %	2.99
	5-Year Yield-on-Cost %	4.42
	Shareholder Yield %	2.95

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	72.87
	Operating Margin %	13.75
	Net Margin %	7.77
	FCF Margin %	22.23
	ROE %	10.61
	ROA %	4.3
	ROIC %	6.64
	ROC (Joel Greenblatt) %	36.59
	ROCE %	10.18
	Years of Profitability over Past 10-Year	10

GF Value Rank

5/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	56.49
	Forward PE Ratio	11.88
	PE Ratio without NRI	32.91
	Shiller PE Ratio	29.38
	Price-to-Owner-Earnings	214.97
	PEG Ratio	2.65
	PS Ratio	4.36
	PB Ratio	6.25
	Price-to-Tangible-Book	299.03
	Price-to-Free-Cash-Flow	19.65
	Price-to-Operating-Cash-Flow	15.05
	EV-to-EBIT	33.08
	EV-to-Forward-EBIT	10.9
	EV-to-EBITDA	22.87
	EV-to-Forward-EBITDA	9.57
	EV-to-Revenue	4.75
	EV-to-Forward-Revenue	4.49
	EV-to-FCF	21.55
	Price-to-Projected-FCF	1.83
	Price-to-Median-PS-Value	1.01
	Price-to-Peter-Lynch-Fair-Value	5.83
	Price-to-Graham-Number	20.65
	Earnings Yield (Greenblatt) %	3.02
	FCF Yield %	5.15
	Forward Rate of Return (Yacktman) %	9.62

Financials (Next Earnings Date:2024-02-02 Est.)

Annual Quarterly TTM

XTER:6MK's 30-Y Financials

Balance Sheet Breakdown

Annual Quarterly

No Enough Data

Cashflow Statement Breakdown

Annual Quarterly

No Enough Data

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

No Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014

Merck & Co Inc Executives

Details

GF Value: €101.5

XTER:6MK

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 4 Medium warning signs with 6MK. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	55,420.077
	EPS (TTM) (€)	1.725
	Beta	0.21
	Volatility %	15.64
	14-Day RSI	37.85
	14-Day ATR (€)	1.522334
	20-Day SMA (€)	95.18
	12-1 Month Momentum %	-5.62
	52-Week Range (€)	92.4 - 109.4
	Shares Outstanding (Mil)	2,534.02

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	4
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Merck & Co Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Merck & Co Inc Stock Events

	Event	Date	Price(€)
No Event Data

Merck & Co Inc Frequently Asked Questions

What is Merck & Co Inc(XTER:6MK)'s stock price today?

The current price of XTER:6MK is €92.70. The 52 week high of XTER:6MK is €109.40 and 52 week low is €92.40.

When is next earnings date of Merck & Co Inc(XTER:6MK)?

The next earnings date of Merck & Co Inc(XTER:6MK) is 2024-02-02 Est..

Does Merck & Co Inc(XTER:6MK) pay dividends? If so, how much?

The Dividend Yield % of Merck & Co Inc(XTER:6MK) is 2.93% (As of Today), Highest Dividend Payout Ratio of Merck & Co Inc(XTER:6MK) was 1.62. The lowest was 0.37. And the median was 0.49. The Forward Dividend Yield % of Merck & Co Inc(XTER:6MK) is 2.99%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
No Press Release

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.